Back to results
US 2017/0320955 A1Published application
Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
AssigneeIgm Biosciences A/S
InventorsBeatrice Tien-Yi Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga
Life of this patent
Estimating the term…
Abstract
This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
Claims24
An isolated IgM antibody or antigen-binding fragment thereof comprising five or six bivalent binding units fragments thereof,
- (a) wherein each binding unit comprises two IgM heavy chain constant regions or fragments thereof, each associated with an antigen-binding domain,
- (b) wherein at least three of the antigen-binding domains of the antibody or fragment thereof specifically and agonistically bind to a tumor necrosis factor (TNF) superfamily receptor protein,
- (c) wherein the antibody or fragment thereof can cross-link at least three identical TNF superfamily receptor proteins expressed on the surface of a cell, thereby activating signal transduction in the cell;
- and
- (d) wherein the antibody or fragment thereof can activate TNF superfamily receptor-mediated signal transduction in a TNF receptor superfamily-expressing cell at a higher potency than an equivalent amount of a bivalent IgG antibody or fragment thereof, which also specifically binds to and agonizes the same TNF superfamily receptor protein.
2 more elements
Dependencies are inferred from the claim text.